HHS earnings analysis
What we found in HHS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q excerpt does not include the current-quarter income statement, balance sheet, cash flow statement, or segment disclosures, so revenue, margin, EPS, cash flow, and working-capital trends cannot be quantified from the filing text provided. The principal development is the proposed Star Equity merger, which introduces substantial completion, execution, and transaction-cost risks. No quantitative company guidance is provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls deemed effective
- The company reported that disclosure controls and procedures were effective at the “reasonable assurance” level as of June 30, 2026.
- Repurchase capacity preserved
- No shares were repurchased during the quarter ended June 30, 2026; $4.1 million remained available under the $6.5 million repurchase authorization.
- Proposed Star Equity merger disclosed
- The filing includes an agreement and plan of merger with Star Holdings Equity dated August 14, 2026, indicating a significant strategic transaction is pending.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Merger completion uncertainty
- Completion of the merger depends on at least 3 stated conditions, including shareholder approval, no prohibiting law or order, and effectiveness of the Form S-4 registration statement; failure to complete the deal could materially and adversely affect the company.
- Potential termination fee exposure
- The merger agreement provides termination rights to both 2 parties—Star Equity and Harte Hanks—and termination under certain circumstances could require a termination fee.
- Merger-related operating constraints
- While the merger is pending, the company faces restrictions on actions including entering contracts, changing employees, incurring indebtedness, making capital expenditures, issuing shares, and settling claims, which could impair operations and execution.
What they said about what is next.
No quantitative revenue or EPS outlook is provided in the supplied 10-Q excerpt. The filing instead focuses on the proposed Star Equity merger and related transaction risks.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Harte Hanks, Inc. reported Q1 2026 results revealing a significant revenue decline of 10.3% year-over-year to $37.3 million and an EPS of -$0.08, which missed consensus estimates. Operating losses increased…
- 10-K · March 17, 2026
- Harte Hanks, Inc. reported a 13.9% decrease in revenue for 2025, totaling $159.6 million, with a net loss of $0.8 million compared to a net loss of $30.3 million in 2024. Operating margins dramatically fell to 0.2%,…
- 10-Q · November 12, 2025
- Harte Hanks' Q3 2025 results reveal significant challenges, with revenues declining 17% year-over-year to $39.52 million and an EPS of -$0.31, reflecting ongoing difficulties in all segments amid a tough economic…
- 10-Q · August 8, 2025
- Harte Hanks reported Q2 2025 results with revenues of $38.6 million, a 14.2% decrease from Q2 2024, and EPS of -$0.05, missing analyst expectations. The company continues to face challenges with declining revenue across…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing HHS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever